Mass General Brigham has spun out AIwithCare, a company commercializing RECTIFIER, an AI tool that automates and enhances clinical trial patient screening using EHR data.
Key Details
- 1RECTIFIER, developed at Mass General Brigham, leverages Retrieval-Augmented Generation (RAG) AI to assess patient eligibility for clinical trials via EHRs, including unstructured notes and reports.
- 2In a 2024 NEJM AI study, RECTIFIER outperformed manual screening methods for a heart failure trial at lower cost.
- 3A randomized-controlled trial involving nearly 4,500 patients showed RECTIFIER doubled the enrollment rate compared to manual screening, with no differences across demographic groups.
- 4RECTIFIER is in use for over 20 clinical and research applications including oncology, neurology, pathology, and cardiology.
- 5Mass General Brigham Innovation facilitated the spinout, aiming for broader deployment across health systems via the AIwithCare platform.
- 6RECTIFIER is also being applied to population health and referral triage, showing >94% accuracy in select use cases.
Why It Matters

Source
EurekAlert
Related News

AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.

AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.

AI-Enhanced Imaging Breaks Barriers in Complex Media for Biomedical Use
Researchers developed a physics-based machine learning imaging system that enhances visibility through complex media, holding promise for biomedical imaging.